Rotmensch H H, Vlasses P H, Ferguson R K
Sackler School of Medicine, Tel-Aviv University, Israel.
Med Clin North Am. 1988 Mar;72(2):399-425. doi: 10.1016/s0025-7125(16)30776-3.
There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure. The hemodynamic, hormonal and clinical effects of the presently available ACE inhibitors, captopril and enalapril, are comparable and their side effect profiles are extremely favorable. One important difference between the two oral ACE inhibitors, however, is their pharmacokinetics; enalapril's action is slower to begin and is of longer duration. Compared with other agents, ACE inhibitors offer important advantages, among them an improved feeling of well being. It is, therefore, expected that ACE inhibitors will gain greater acceptance by patients and physicians in the future.
有令人信服的证据表明,血管紧张素转换酶(ACE)抑制剂单独使用或与利尿剂联合使用,能有效降低各种程度原发性或肾血管性高血压患者的血压,而且作为充血性心力衰竭患者的辅助治疗药物,它们具有特别的益处。目前可用的ACE抑制剂卡托普利和依那普利的血流动力学、激素及临床效果相当,且副作用极小。然而,这两种口服ACE抑制剂之间一个重要的区别在于它们的药代动力学;依那普利起效较慢但持续时间更长。与其他药物相比,ACE抑制剂具有重要优势,其中包括能改善健康感觉。因此,预计ACE抑制剂未来将更受患者和医生的认可。